Sun Pharma Advanced Research Company profit and loss

Latest FY26

Revenue: ₹1,879cr+2,518.3% on FY25
EBITDA: ₹1,599cr−₹323 cr in FY25
Net profit: ₹1,553cr−₹343 cr in FY25
EPS: ₹47.86−₹10.55 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,909	1,879	71.8	75.6	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	25.5	11.0	1.8	29.5	—
	1,935	1,890	73.6	105	250
	26.1	23.6	23.1	28.1	—
	116	118	154	142	107
	36.1	34.1	9.0	1.7	—
	9.7	10.2	12.4	12.5	—
	150	139	218	308	—
	338	325	416	492	472
	1,617	1,599	−323	−402	—
	1,607	1,589	−336	−415	—
Profit
	1,597	1,565	−343	−387	—
	−12.4	−12.4	0.0	0.0	—
	1,584	1,553	−343	−387	—
	−0.3	−0.2	−0.3	1.6	—
	0.2	0.0	0.0	−1.3	—
	−0.1	−0.2	−0.3	0.4	—
	1,584	1,553	−343	−387	—
	1,584	1,553	−343	−387	—
	2.6	2.6	−0.2	0.2	—
	1,587	1,556	−343	−387	—
	—	1,556	−343	—	—
Per share
	₹48.81	₹47.86	−₹10.55	−₹11.93	—
	−₹5.46	₹0.00	−₹10.55	−₹11.93	—
Other comprehensive income — detail
	2.6	2.6	−0.2	—	—
	—	2.6	—	—	—
	0.0	0.0	0.3	—	—
	—	—	—	−0.2	—
	—	—	−0.1	—	—
	—	—	—	−0.0	—
	—	1,558	−343	—	—
Per share — as-filed variants
	₹48.81	₹47.86	−₹10.55	−₹11.93	—
	−₹5.46	₹0.00	−₹10.55	−₹11.93	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,883	1,856	48.7	47.4	—
	98.6%	98.7%	67.8%	62.8%	—
Adjusted (ex-exceptional items) — derived
	1,597	1,565	−343	−387	—
	−12.4	−12.4	0.0	0.0	—
	1,597	1,566	−343	−387	—
	₹49.19	₹48.24	−₹10.55	−₹11.93	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSTAR SHILPAMED SUPRIYA THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹5,938 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	—	75.6	71.8	1,879.2	1,909.5
Other Income	—	29.5	1.8	11.0	25.5
Total Income	249.7	105.0	73.6	1,890.1	1,934.9
Expenses
+ Cost of Materials Consumed	—	28.1	23.1	23.6	26.1
+ Employee Benefit Expense	107.0	141.8	153.6	118.0	116.3
+ Finance Costs	—	1.7	9.0	34.1	36.1
+ Depreciation & Amortisation	—	12.5	12.4	10.2	9.7
+ Other Expenses	—	307.7	218.2	138.8	150.2
Total Expenses	472.2	491.9	416.3	324.8	338.4
EBITDA	—	-402.1	-323.1	1,598.8	1,616.8
EBIT	—	-414.6	-335.5	1,588.6	1,607.1
Profit
PBT before Exceptional Items	—	-386.8	-342.8	1,565.4	1,596.5
+ Exceptional Items	—	0.0	0.0	-12.4	-12.4
Pretax Income	—	-386.8	-342.8	1,553.0	1,584.2
+ Current Tax	—	1.6	-0.3	-0.2	-0.3
+ Deferred Tax	—	-1.3	0.0	0.0	0.2
Tax Expense	—	0.4	-0.3	-0.2	-0.1
Net Income	—	-387.2	-342.5	1,553.2	1,584.3
+ Net Income — Continuing Ops	—	-387.2	-342.5	1,553.2	1,584.3
+ Other Comprehensive Income	—	0.2	-0.2	2.6	2.6
Total Comprehensive Income	—	-387.0	-342.7	1,555.8	1,586.9
Net Income to Common	—	—	-342.7	1,555.8	—
Per Share
Basic EPS	—	-11.93	-10.55	47.86	48.81
Diluted EPS	—	-11.93	-10.55	0.00	-5.46
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.2	2.6	2.6
+ Items NOT to be Reclassified to P&L	—	—	—	2.6	—
+ Tax on Items NOT to be Reclassified	—	—	0.3	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	—	-0.2	—	—	—
+ Tax on Items to be Reclassified	—	—	-0.1	—	—
+ Tax on Items to be Reclassified — alt tag	—	-0.0	—	—	—
Comprehensive Income — Owners of Parent	—	—	-342.9	1,558.3	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	-11.93	-10.55	47.86	48.81
Diluted EPS — Continuing Operations	—	-11.93	-10.55	0.00	-5.46
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	—	47.4	48.7	1,855.6	1,883.3
Gross Margin %	—	62.77	67.79	98.74	98.63
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	—	-386.8	-342.8	1,565.4	1,596.5
− Exceptional Items (reconciliation)	—	0.0	0.0	-12.4	-12.4
Net Income Adj (tax-effected)	—	-387.2	-342.5	1,565.6	1,596.7
EPS Adj	—	-11.93	-10.55	48.24	49.19
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	1.00	1.00	1.00	1.00
Paid Up Equity Capital	—	32.5	32.5	32.5	32.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.